{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981470919023232.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/art.24232"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.24232"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.24232"}}],"dc:title":[{"@value":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Antiphospholipid antibodies (aPL), namely anticardiolipin antibodies (aCL) and lupus anticoagulant (LAC), have been associated with an increased risk of thrombosis in systemic lupus erythematosus (SLE). We examined additional thrombosis risk factors (aPL profile, SLE‐related, and traditional risk factors) and the primary thrombosis prevention in SLE patients with and without aPL.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>All SLE patients with positive aPL but without previous thrombotic manifestations who were regularly followed up at our department (n = 144) and 144 age‐ and sex‐matched SLE patients with negative aPL were included in this study. The median followup times were 104 and 112 months, respectively. The demographic, clinical, laboratory, and treatment characteristics and the traditional thrombosis risk factors were recorded.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The thrombosis rate was 29 per 144 aPL‐positive patients (20.1%) and 11 per 144 aPL‐negative patients (7.6%; <jats:italic>P</jats:italic> = 0.003). In multiadjusted analysis, significant predictors of thrombosis were male sex (hazard ratio [HR] 6.25, <jats:italic>P</jats:italic> < 0.01), LAC (HR 3.48, <jats:italic>P</jats:italic> = 0.04), and constantly positive aCL (HR 5.87, <jats:italic>P</jats:italic> = 0.01) for aPL‐positive patients, while male sex (HR 7.14, <jats:italic>P</jats:italic> = 0.03) and hypertension were predictors for aPL‐negative patients (HR 6.49, <jats:italic>P</jats:italic> = 0.03). Additionally, the duration of low‐dose aspirin treatment played a protective role against thrombosis in aPL‐positive patients (HR per month 0.98, <jats:italic>P</jats:italic> = 0.05), as did the duration of hydroxychloroquine in both aPL‐positive (HR per month 0.99, <jats:italic>P</jats:italic> = 0.05) and aPL‐negative patients (HR per month 0.98, <jats:italic>P</jats:italic> = 0.04).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Independent predictors of thrombosis for aPL‐positive patients were male sex, LAC, and constantly positive aCL, and for aPL‐negative patients were male sex and hypertension. The duration of low‐dose aspirin use played a protective role against thrombosis in aPL‐positive patients as did the duration of hydroxychloroquine in both groups.</jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981470919023234","@type":"Researcher","foaf:name":[{"@value":"Maria G. Tektonidou"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470919023232","@type":"Researcher","foaf:name":[{"@value":"Katerina Laskari"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470919023235","@type":"Researcher","foaf:name":[{"@value":"Demosthenes B. Panagiotakos"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470919023233","@type":"Researcher","foaf:name":[{"@value":"Haralampos M. Moutsopoulos"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"08937524"},{"@type":"EISSN","@value":"15290123"}],"prism:publicationName":[{"@value":"Arthritis Care & Research"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2008-12-30","prism:volume":"61","prism:number":"1","prism:startingPage":"29","prism:endingPage":"36"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.24232"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.24232"}],"createdAt":"2008-12-31","modifiedAt":"2023-11-14","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360283693875326592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165427157504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185415716224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185415725312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567188247030784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"β2‐Glycoprotein I‐Dependent Anti‐Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360849945392764288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869854346398336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679849711360","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Antiphospholipid Antibodies and Renal Outcomes in Patients with Lupus Nephritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564227332400896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Glomerular Injury Is Exacerbated in Lupus-Prone MRL/lpr Mice Treated with a Protease-Activated Receptor 2 Antagonist"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238088386816","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845712968164736","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"抗リン脂質抗体症候群"},{"@language":"en","@value":"Antiphospholipid syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1390849376469023872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/2051996266985195904","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/art.24232"},{"@type":"CROSSREF","@value":"10.1177/0961203315578765_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.1007/s10157-018-1659-y_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.2491/jjsth.29.294_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.1007/s11926-017-0674-4_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.1111/1756-185x.13387_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.1111/1756-185x.13418_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.1902/jop.2015.140664_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.48.2363_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1999-18_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.1111/1756-185x.13792_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.1136/lupus-2024-001223_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5042-20_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"},{"@type":"CROSSREF","@value":"10.1620/tjem.249.127_references_DOI_1pJShBcGePuoqt7B0epEnyypF6W"}]}